MOBX earnings analysis
What we found in MOBX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Mobix Labs reported approximately $970,000 of revenue, down from approximately $2.0 million in both the prior quarter and prior-year quarter. Gross margin declined to 19.0% and operating margin deteriorated to -627.9%, although diluted EPS improved to -$0.59 from -$1.60 sequentially. The company disclosed ineffective disclosure controls and multiple material weaknesses, while restrictive financing terms, potential cash redemption obligations, and substantial prospective dilution—including 4,800,000 shares for the SPD acquisition—remain significant concerns.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue contracted sharply
- Revenue was approximately $970,000, down from approximately $2.0 million in 2026 Q1 and $2.0 million in 2025 Q2, indicating a sharp sequential and year-over-year contraction.
- Gross margin deteriorated
- Gross margin fell to 19.0% from 31.0% in the prior quarter and 57.4% in the prior-year quarter, a sequential decline of 12.0 percentage points and year-over-year decline of 38.4 points.
- Operating losses intensified
- Operating margin was -627.9%, worse than -471.1% in the prior quarter and -343.4% in the prior-year quarter, reflecting continued heavy operating losses relative to revenue.
- EPS loss improved but remains severe
- Diluted EPS was -$0.59 versus -$1.60 in the prior quarter and -$1.70 in the prior-year quarter; the loss per share improved, but remains deeply negative amid the revenue decline.
- SPD acquisition expands strategic scope
- The company agreed to acquire SPD for 4,800,000 shares of Class A common stock with no cash consideration, subject to stockholder approval and other customary closing conditions.
- Control remediation is underway
- Management stated that remediation of the identified control weaknesses is expected to result in significant future costs, including hiring additional accounting and IT personnel and implementing a more sophisticated IT system.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material weaknesses threaten reporting quality
- Management concluded that disclosure controls were not effective as of June 30, 2026 and identified material weaknesses affecting control environment, risk assessment, accounting policies, complex transactions, transaction authorization, and IT general controls. The weaknesses have resulted in adjustments to numerous accounts and disclosures, including purchase-price allocations for business combinations in the interim period ended June 30, 2026.
- Financing covenants constrain flexibility
- The Series A 10% Convertible Preferred Stock and convertible notes impose restrictions on additional debt, securities issuance, dividends, repurchases, mergers, and asset sales. Certain notes are secured by liens on company assets, potentially constraining financing and liquidity.
- Convertible securities create dilution risk
- The floating, discounted conversion terms and anti-dilution provisions could result in substantially more shares being issued than anticipated. The company has already issued 585,365 shares on August 5, 2026 and another 585,365 shares on August 13, 2026 from conversions at $2.05 per share.
- Potential cash redemption pressure
- Upon specified triggering events or defaults, holders may require cash redemption or repayment at a premium, with penalties and default interest. The company stated it does not currently have sufficient cash on hand to fund redemption or repayment of the Series A 10% Convertible Preferred Stock and convertible notes.
- Acquisition strategy may strain resources
- The SPD transaction would issue 4,800,000 shares, while the company also expects to pursue additional acquisitions under its NSM Initiative. The filing warns that acquisitions may require capital, cause substantial dilution, and strain management resources.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.59
- Gross margin
- 19.0%
- Operating margin
- -627.9%
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the extracted 10-Q. The filing does state that remediation of material weaknesses is expected to result in significant future costs.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 20, 2026
- Mobix Labs, Inc. reported total revenue of $2.511 million for Q2 2026, a substantial decline of 61% compared to the same quarter last year. The company also recorded a net loss of $5.853 million, reflecting a 155%…
- 10-Q · February 12, 2026
- Mobix Labs reported quarterly revenue of $1,875,000 (reported as $1,875 in the filing in thousands), down from $3,169,000 a year earlier, with gross profit of $581,000 and a net loss of $10,125,000 for the quarter.…
- 10-Q · August 13, 2025
- Mobix Labs reported quarter net revenue of $2,350 (reported in the filing in thousands) vs $2,058 in the year-ago quarter, with gross profit rising to $1,349. The company remains unprofitable (net loss $8,272 for the…
- 10-Q · February 12, 2025
- Mobix Labs reported quarterly revenue of $3,169,000 (vs. $285,000 a year ago) and GAAP loss per share of $(0.52). Gross profit turned positive at $1,687,000 (gross margin 53.2%), but the company recorded a large loss…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MOBX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever